Plasma Extender

Stephen Massia (Inventor)

Research output: Patent

Abstract

Massive blood loss via penetrating trauma requires immediate administration of resuscitative fluids. A major limitation of these fluids is that vital blood-borne factors that suppress hemorrhaging are not replaced and residual circulating clotting factors are diluted. Furthermore, the migration of inflammatory cells activated by rapid blood loss can result in multiple system organ failure. Current treatments of hemorrhagic shock outside of medical facilities are typically less effective than those available in hospitals and are often inadequate to sustain life.Researchers at Arizona State University are working with biomimetic materials that can control hemorrhages and limit inflammatory cell migration. These materials not only act as plasma extenders, but also actively interact with forming clots. In addition, factors can be added that selectively bind to inflamed tissues forming a barrier to trauma-induced inflammatory cell migration. As a combined therapy, this material system may be effective in significantly reducing systemic tissue damage or organ failure by blocking inflammatory cell migration and limiting the loss of fluids and other blood-borne factors.
Original languageEnglish (US)
StatePublished - Oct 10 2001

Fingerprint

Cell Movement
Biomimetic Materials
Blood Coagulation Factors
Multiple Organ Failure
Hemorrhagic Shock
Wounds and Injuries
Research Personnel
Hemorrhage
Therapeutics

Cite this

Massia S, inventor. Plasma Extender. 2001 Oct 10.
@misc{5152ae765ebb4a23b076d0b6cb9aae2a,
title = "Plasma Extender",
abstract = "Massive blood loss via penetrating trauma requires immediate administration of resuscitative fluids. A major limitation of these fluids is that vital blood-borne factors that suppress hemorrhaging are not replaced and residual circulating clotting factors are diluted. Furthermore, the migration of inflammatory cells activated by rapid blood loss can result in multiple system organ failure. Current treatments of hemorrhagic shock outside of medical facilities are typically less effective than those available in hospitals and are often inadequate to sustain life.Researchers at Arizona State University are working with biomimetic materials that can control hemorrhages and limit inflammatory cell migration. These materials not only act as plasma extenders, but also actively interact with forming clots. In addition, factors can be added that selectively bind to inflamed tissues forming a barrier to trauma-induced inflammatory cell migration. As a combined therapy, this material system may be effective in significantly reducing systemic tissue damage or organ failure by blocking inflammatory cell migration and limiting the loss of fluids and other blood-borne factors.",
author = "Stephen Massia",
year = "2001",
month = "10",
day = "10",
language = "English (US)",
type = "Patent",

}

TY - PAT

T1 - Plasma Extender

AU - Massia, Stephen

PY - 2001/10/10

Y1 - 2001/10/10

N2 - Massive blood loss via penetrating trauma requires immediate administration of resuscitative fluids. A major limitation of these fluids is that vital blood-borne factors that suppress hemorrhaging are not replaced and residual circulating clotting factors are diluted. Furthermore, the migration of inflammatory cells activated by rapid blood loss can result in multiple system organ failure. Current treatments of hemorrhagic shock outside of medical facilities are typically less effective than those available in hospitals and are often inadequate to sustain life.Researchers at Arizona State University are working with biomimetic materials that can control hemorrhages and limit inflammatory cell migration. These materials not only act as plasma extenders, but also actively interact with forming clots. In addition, factors can be added that selectively bind to inflamed tissues forming a barrier to trauma-induced inflammatory cell migration. As a combined therapy, this material system may be effective in significantly reducing systemic tissue damage or organ failure by blocking inflammatory cell migration and limiting the loss of fluids and other blood-borne factors.

AB - Massive blood loss via penetrating trauma requires immediate administration of resuscitative fluids. A major limitation of these fluids is that vital blood-borne factors that suppress hemorrhaging are not replaced and residual circulating clotting factors are diluted. Furthermore, the migration of inflammatory cells activated by rapid blood loss can result in multiple system organ failure. Current treatments of hemorrhagic shock outside of medical facilities are typically less effective than those available in hospitals and are often inadequate to sustain life.Researchers at Arizona State University are working with biomimetic materials that can control hemorrhages and limit inflammatory cell migration. These materials not only act as plasma extenders, but also actively interact with forming clots. In addition, factors can be added that selectively bind to inflamed tissues forming a barrier to trauma-induced inflammatory cell migration. As a combined therapy, this material system may be effective in significantly reducing systemic tissue damage or organ failure by blocking inflammatory cell migration and limiting the loss of fluids and other blood-borne factors.

M3 - Patent

ER -